# US 2026/0242349 A1 · N,n'-sulfonimidamides as anticancer, antiinflammatory, antifibrotic and neuroprotective agents

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0242349 A1
- Document ID: US20260242349A1
- Status: Published application
- Kind: A1
- Application number: 19/159,289
- Filed: 2024-02-27
- Published: 2026-08-20
- Earliest claimed: 2023-02-27
- Assignees: Atux Iskay LLC
- Applicants: Atux Iskay LLC
- Inventors: Michael Ohlmeyer
- Web page: https://patentgrep.com/patent/US20260242349A1

## CPC

- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- A61K 31/451: having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
- A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- C07D 211/96: Sulfur atom
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A genus of N,N′-sulfonimidamides is disclosed. The compounds are of the following genus: Formula (i) or a pharmaceutically acceptable salt thereof. The compounds are useful in the treatment of a variety of disorders, including as a monotherapy in cancer treatment, or used in combination with other drugs to restore sensitivity to chemotherapy where resistance has developed.

## Claims

### Claim 1

A compound of formula I:
or a pharmaceutically acceptable salt thereof,
wherein:
A is N or CH
B is absent or is selected from a direct bond, —CH2CH2—, —CH═CH—, O, S, or —NRB—C(O)—;
R1 is selected from CH2 and may also be —O— or NRQ when A is CH only;
R2 is selected from CH2 or R1 and R2 taken together may for a carbon-carbon double bond;
Rim is selected from H or lower alkyl
U, V and W are independently cabocyclic aromatic or heteroaromatic rings;
n=0 or 1;
X1, X2, X3 and X4 are independently selected in each instance from hydrogen, halogen, nitro, cyano, (C1-C6)alkyl optionally substituted with —OH, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)haloalkylthio, —NR3R4, —OR3, —C(O)R3, —OC(O)R3, —C(O)NR3R4, —C(O)OR3, —SR3, —SO2R3, and —SO2NR3R4;
Z1 and Z2 are independently selected in each instance from hydrogen, halogen, nitro, cyano, azido, (C1-C6)alkyl, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, (C1-C6)haloalkylthio, —NR3R4, —NR3C(O)R4, —NR3C(O)OR5, —OR3, —C(O)R3, —OC(O)R3, —C(O)NR3R4, —C(O)OR3, —SR3, —SO2R3, —SO2NR3R4, and five membered heterocyclyl;
RB is selected from H, or lower alkyl
RQ is selected from H, optionally substituted lower alkyl, aryl
R3, R4 and R5 are lower alkyl.

### Claim 2 (depends on 1)

The compound of claim 1 where A is N.

### Claim 3 (depends on 1)

The compound of claim 1 where A is CH.

### Claim 4 (depends on 1, 2, 3)

The compound of claim any one of claims 1-3, wherein X1, X2, X3 and X4 are independently selected in each instance from hydrogen and halogen.

### Claim 5 (depends on 1, 2, 3, 4)

The comopound of any one of claims 1-4, wherein Z1 and Z2 are independently selected in each instance from hydrogen and (C1-C6)haloalkoxy.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The compound of any one of claims 1-5, wherein B is a direct bond or —CH2CH2—.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The compound of any one of claims 1-6, wherein R1 and R2 are both CH2.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The compound of any one of claims 1-7, wherein Rim is H.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The compound of any one of claims 1-8, wherein n is 1.

### Claim 10 (depends on 1)

The compound of claim 1, selected from
or a pharmaceutically acceptable salt thereof.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

A composition, comprising the compound of any one of claims 1-10.

### Claim 12 (depends on 11)

The composition of claim 11, which is a pharmaceutical composition further comprising at least one pharmaceutically acceptable carrier.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

A method of treating a disease related to deficient Protein Phosphatase 2A (PP2A) activity in a subject, comprising administering the compound of any one of claims 1-10, or the composition of claim 11 or claim 12, to a subject in need thereof.

### Claim 14 (depends on 13)

The method of claim 13, wherein the disease is a cancer, an inflammatory disease, an autoimmune disease, a fibrotic disease, or a neurodegenerative disease.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14)

The method of claim 14, wherein the cancer is resistant to at least one previous therapy that was administered to the subject, and administration of the compound of any one of claims 1-10, or the composition of claim 11 or claim 12 resensitizes the cancer to said previous therapy.

### Claim 16 (depends on 13)

The method of claim 13, wherein the disease is prostate cancer, breast cancer, lung fibrosis, or Alzheimer's disease.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

A method of inhibiting a kinase, comprising contacting the kinase with the compound of one of claims 1-10, or the composition of claim 11 or claim 12.

### Claim 18 (depends on 17)

The method of claim 17, which is an in vivo method.

### Claim 19 (depends on 17)

The method of claim 17, which is an in vitro method.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

An article of manufacture, comprising the compound of one of claims 1-10, or the composition of claim 11 or claim 12.
